Hatchtech

hatchtech.com.au

Hatchtech is an Australian biotechnology company focused on developing innovative treatments for head lice, particularly through its FDA-approved product, Xeglyze®. This next-generation pediculicide offers a unique mechanism of action with a single 10-minute application, eliminating the need for nit combing. The product is designed to address the growing resistance to traditional treatments, providing a more effective solution for the over 100 million head lice infestations globally each year. With strong publication support and established manufacturing supply chains, Hatchtech is well-positioned in the pediatric and dermatology markets, aiming for global registration opportunities and immediate product sales.